Advanced Search

Targeting the tight junction : immunotherapy of colon cancer

Research and Teaching Output of the MIT Community

Show simple item record

dc.contributor.advisor K. Dane Wittrup. en_US Ackerman, Margaret E en_US
dc.contributor.other Massachusetts Institute of Technology. Dept. of Biology. en_US 2011-05-23T18:03:54Z 2011-05-23T18:03:54Z 2009 en_US 2010 en_US
dc.description Thesis (Ph. D.)--Massachusetts Institute of Technology, Dept. of Biology, February 2010. en_US
dc.description "February 2010." Cataloged from PDF version of thesis. en_US
dc.description Includes bibliographical references. en_US
dc.description.abstract A33 is a cell surface glycoprotein of colon epithelium with a long clinical history as a target in antibody-based cancer therapy. Despite being present in normal colon, radio-labeled antibodies against A33 are selectively retained by tumors at long time points. Accordingly, we have studied the trafficking and kinetic properties of the antigen to determine its promise in multi-step, pretargeted immunotherapy. In vitro, the localization, mobility, and persistence of the antigen were investigated, and this work has demonstrated that the antigen is both highly immobile and extremely persistent, properties which may contribute to the prolonged retention of the clinically administered antibodies, and their uncommon ability to penetrate solid tumors. Secondly, because poor tissue penetration is a significant obstacle to the development of successful antibody drugs for immunotherapy of solid tumors, we assess the contribution of antigen density and turnover rate by evaluating the distance to which antibodies penetrate spheroids when these properties are systematically varied. The results agree well with the quantitative modeling predictions, and demonstrate that dosing distal regions of tumors is best achieved by selecting slowly internalized targets that are not expressed above the level necessary for recruiting a toxic dose of therapeutic. Lastly, we describe the in vitro characteristics and report the promising in vivo biodistribution of a multi-step tumor targeting therapy utilizing a novel bispecific antibody which recognizes both the A33 antigen and a small molecule radiometal chelate. Following these studies, several protein engineering techniques are presented. First, a new method of conducting de novo protein engineering utilizing highly avid magnetic beads is described, in which extremely weak interactions can be captured from large library populations. Secondly, an in vitro assay which utilizes these highly avid magnetic beads is used to score the clinical immunogenicity of therapeutic protein drugs is presented. Finally, the use of sortase A as a means to generate fusion proteins posttranslationally is described. Taken together, this additional work demonstrates a productive intersection of basic research and protein engineering methods. en_US
dc.description.statementofresponsibility by Margaret E. Ackerman. en_US
dc.format.extent 188 p. en_US
dc.language.iso eng en_US
dc.publisher Massachusetts Institute of Technology en_US
dc.rights M.I.T. theses are protected by copyright. They may be viewed from this source for any purpose, but reproduction or distribution in any format is prohibited without written permission. See provided URL for inquiries about permission. en_US
dc.rights.uri en_US
dc.subject Biology. en_US
dc.title Targeting the tight junction : immunotherapy of colon cancer en_US
dc.title.alternative Immunotherapy of colon cancer en_US
dc.type Thesis en_US Ph.D. en_US
dc.contributor.department Massachusetts Institute of Technology. Dept. of Biology. en_US
dc.identifier.oclc 720986513 en_US

Files in this item

Name Size Format Description
720986513-MIT.pdf 15.61Mb PDF Full printable version

This item appears in the following Collection(s)

Show simple item record